6108 — New Ray Medicine International Holding Share Price
Last trade - 00:00- HK$61.86m
- -HK$41.81m
- HK$50.15m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.13 | ||
| Price to Tang. Book | 0.13 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.23 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -3.75% | ||
| Return on Equity | -4.41% | ||
| Operating Margin | -36.37% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | HK$m | 118.63 | 133.21 | 335.38 | 89.77 | 50.15 | n/a | n/a | -33.03% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
New Ray Medicine International Holding Limited is an investment holding company principally engaged in the trading of pharmaceutical products in China. The Company operates its business through four segments. The Injection Drugs segment is engaged in the trading of injection drugs. The Capsule and Granule Drugs segment is engaged in the trading of capsule and granule drugs. The Tablet Drugs segment is engaged in the trading of tablet drugs. The Others segment is engaged in the trading of miscellaneous types of goods and drugs.
Directors
- Qiuqin Wang CHM (40)
- Kwok Wa Lai CTR (31)
- Xueping Chu EDR (49)
- Zhihong Huo EDR (41)
- Linxing He OTH (40)
- Chi Kin Leung NID (65)
- Sin Ming Li NID (41)
- Lai Yin Sy NID (37)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- August 9th, 2012
- Public Since
- October 25th, 2013
- No. of Employees
- 23
- Sector
- Food & Drug Retailing
- Industry
- Consumer Defensives
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 1,671,847,000
- Address
- Room 3702-03, Dikai International Center, HANGZHOU
- Web
- http://www.newraymedicine.com
- Phone
- Auditors
- Moore Stephens CPA Limited
Upcoming Events for 6108
Similar to 6108
Alibaba Health Information Technology
Stock Exchange of Hong Kong Limited
Alpha Professional Holdings
Stock Exchange of Hong Kong Limited
Asia Grocery Distribution
Stock Exchange of Hong Kong Limited
Best Mart 360 Holdings
Stock Exchange of Hong Kong Limited
Beijing Properties (Holdings)
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 19:15 UTC, shares in New Ray Medicine International Holding are trading at HK$0.04. This share price information is delayed by 15 minutes.
Shares in New Ray Medicine International Holding last closed at HK$0.04 and the price had moved by -54.32% over the past 365 days. In terms of relative price strength the New Ray Medicine International Holding share price has underperformed the FTSE Developed Asia Pacific Index by -54.01% over the past year.
There is no consensus recommendation for this security.
New Ray Medicine International Holding does not currently pay a dividend.
New Ray Medicine International Holding does not currently pay a dividend.
New Ray Medicine International Holding does not currently pay a dividend.
To buy shares in New Ray Medicine International Holding you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$0.04, shares in New Ray Medicine International Holding had a market capitalisation of HK$61.86m.
Here are the trading details for New Ray Medicine International Holding:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 6108
Based on an overall assessment of its quality, value and momentum New Ray Medicine International Holding is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like New Ray Medicine International Holding. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -30.1%.
As of the last closing price of HK$0.04, shares in New Ray Medicine International Holding were trading -21.4% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The New Ray Medicine International Holding PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$0.04.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
New Ray Medicine International Holding's management team is headed by:
- Qiuqin Wang - CHM
- Kwok Wa Lai - CTR
- Xueping Chu - EDR
- Zhihong Huo - EDR
- Linxing He - OTH
- Chi Kin Leung - NID
- Sin Ming Li - NID
- Lai Yin Sy - NID